Healthcare

Abbott Laboratories has called a halt to its European flu-vaccine sale because of a dissapointing run of initial bids, The Wall Street Journal reported.

Abbott Laboratories has called a halt to its European flu-vaccine sale because of a dissapointing run of initial bids, The Wall Street Journal reported.

Abbott Laboratories has called a halt to its European flu-vaccine sale because of a dissapointing run of initial bids, The Wall Street Journal reported.

Abbott Laboratories has called a halt to its European flu-vaccine sale because of a dissapointing run of initial bids, The Wall Street Journal reported.